EGFR and gastric cancer: Rao et al. carriet out a phase I study of M combined with the ECX regimen (epirubicin/cis/cape) as first-line therapy for patients with EGFR positive GC and GEJ cancer by IHC1atients screened, 47% had EGFR-positive tumors.